Bioblast pharma ltd. (ENLV)
CashFlow / Yearly
Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Cash flows from operating activities:
Net loss

-5,945

-16,022

-15,365

-7,022

-1,145

-229

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and disposal of property and equipment

-

-

-

5

-

-

Depreciation

64

38

17

-

0

0

Share-based compensation, net

408

700

2,623

736

254

9

Interest on short-term deposit

-7

-39

18

28

0

0

Changes in operating assets and liabilities:
Decrease (increase) in receivables and prepaid expenses

-567

-399

786

245

19

10

Decrease (increase) in long-term deposit

-18

-13

24

4

5

0

Increase (decrease) in trade payables

-681

-712

127

1,239

-28

74

Increase (decrease) in other accounts payable

-790

129

107

910

78

7

Increase (decrease) in accrued severance pay

0

-70

70

-

-

-

Net cash used in operating activities

-6,352

-15,486

-13,249

-

-

-

Cash flow from investing activities:
Change in short term bank deposits

-3,000

-9,000

-10,000

-

-

-

Proceeds from sale of property and equipment

9

0

0

-

-

-

Increase (decrease) in long-term liabilities

-

-

-

0

0

-

Net cash used in operating activities

-

-

-

-4,409

-865

-149

Withdrawal of (investment in) short-term bank deposits

-

-

-

22,000

0

0

Purchase of property and equipment

2

18

48

63

2

0

Net cash provided by (used in) investing activities

3,007

8,982

9,952

-

-

-

Cash flow from financing activities:
Proceeds from exercise of options

0

0

0

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-22,063

-2

0

Issuance of shares, net

0

6,089

0

36,785

991

295

Net cash provided by financing activities

0

6,089

0

-

-

-

Net cash provided by financing activities

-

-

-

36,785

991

295

Decrease in cash and cash equivalents

-3,345

-415

-3,297

10,313

124

146

Supplemental disclosures of cash flow information:
Cash paid for taxes

32

210

4

0

-

-

Cash received for interest

43

120

162

57

-

-